Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (LXRX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · LXRX · as of Jun 8, 2026
Activity summary
Buy transactions
8
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Lexicon Pharmaceuticals, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
LXRX insider buying and selling by quarter
LXRX insider selling · LXRX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · LXRX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
LXRX executive sell shares · LXRX board member insider trading · LXRX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 3, 2026 | Swain Judith L Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | Sullivan Diane E. Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | Cheung Ivan Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | BARKER SAM L Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | Amouyal Philippe Director | Option | 89,312 | — | Form 4 |
| Jun 3, 2026 | DEBBANE RAYMOND Director | Option | 89,312 | — | Form 4 |
| Apr 30, 2026 | Artal Participations S.a r.l. Director | Option | 20,421,735 | — | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option | 144,393 | — | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Other | 68,107 | $100K | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option | 52,316 | — | Form 4 |
| Feb 28, 2026 | McDermott Wendy SVP, Human Resources | Option | 27,697 | — | Form 4 |
| Feb 28, 2026 | Martens Rachel Yap SVP, Partnerships & Corp Strat | Option | 67,090 | — | Form 4 |
| Feb 28, 2026 | Martens Rachel Yap SVP, Partnerships & Corp Strat | Other | 35,826 | $53K | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option | 202,260 | — | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Other | 109,098 | $160K | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option | 74,226 | — | Form 4 |
| Feb 28, 2026 | Granowitz Craig B SVP, Chief Medical Officer | Option | 35,790 | — | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option | 65,640 | — | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Other | 24,338 | $36K | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option | 20,310 | — | Form 4 |
| Feb 28, 2026 | Gopinathan Suma SVP, Discovery | Option | 14,000 | — | Form 4 |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Option | 128,190 | — | Form 4 |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Other | 74,572 | $110K | Form 4 |
| Feb 28, 2026 | DeFrancesco Lisa SVP, IR and Corp Comm | Option | 24,674 | — | Form 4 |
Artal Participations S.a r.l.
Director
Date
Apr 30
Shares
20,421,735
Price
—
Value
—
McDermott Wendy
SVP, Human Resources
Date
Feb 28
Shares
68,107
Price
$1.47
Value
$100K
Martens Rachel Yap
SVP, Partnerships & Corp Strat
Date
Feb 28
Shares
67,090
Price
—
Value
—
Martens Rachel Yap
SVP, Partnerships & Corp Strat
Date
Feb 28
Shares
35,826
Price
$1.47
Value
$53K
Granowitz Craig B
SVP, Chief Medical Officer
Date
Feb 28
Shares
202,260
Price
—
Value
—
Granowitz Craig B
SVP, Chief Medical Officer
Date
Feb 28
Shares
109,098
Price
$1.47
Value
$160K
Granowitz Craig B
SVP, Chief Medical Officer
Date
Feb 28
Shares
74,226
Price
—
Value
—
Granowitz Craig B
SVP, Chief Medical Officer
Date
Feb 28
Shares
35,790
Price
—
Value
—
DeFrancesco Lisa
SVP, IR and Corp Comm
Date
Feb 28
Shares
128,190
Price
—
Value
—
DeFrancesco Lisa
SVP, IR and Corp Comm
Date
Feb 28
Shares
74,572
Price
$1.47
Value
$110K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About LXRX insider trading
LXRX insider trades
Lexicon Pharmaceuticals, Inc. (LXRX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including DEBBANE RAYMOND (Director), McDermott Wendy (SVP, Human Resources), Granowitz Craig B (SVP, Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. LXRX insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Lexicon Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
LXRX insider trading · 5 questionsThe insiders of Lexicon Pharmaceuticals, Inc. (LXRX) include executives and directors such as DEBBANE RAYMOND (Director), McDermott Wendy (SVP, Human Resources), Granowitz Craig B (SVP, Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026